Recombinant Human Matrix Gla Protein (MGP) Protein (His)

Name: Recombinant Human Matrix Gla Protein (MGP) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03138P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Matrix Gla Protein (MGP) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P08493
Target Symbol	MGP
Synonyms	Cell growth inhibiting gene 36 protein; Cell growth-inhibiting gene 36 protein; GAMMA-CARBOXYGLUTAMIC ACID PROTEIN, MATRIX; GIG36; Matrix Gla protein; MGLAP; MGP; MGP_HUMAN; NTI
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	YESHESMESYELNPFINRRNANTFISPQQRWRAKVQERIRERSKPVHELNREACDDYRLCERYAMVYGYNAAYNRYF
Expression Range	20-96aa
Protein Length	Full Length of Mature Protein
Mol. Weight	13.5kDa
Research Area	Developmental Biology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation.
Subcellular Location	Secreted.
Protein Families	Osteocalcin/matrix Gla protein family
Database References	HGNC: 7060 OMIM: 154870 KEGG: hsa:4256 UniGene: PMID: 29303985 Study found an association between diastolic left ventricular function with circulating inactive desphospho-uncarboxylated MGP in two cohorts; undertook histological studies confirming the presence of MGP in the heart and determining its exact localization in healthy and diseased hearts, using conformation-specific MGP antibodies. PMID: 29529056 Studied serum levels of bone morphogenic protein-4 (BMP-4) and matrix Gla protein (MGP) in patients who were admitted to emergency department with the diagnosis of acute coronary syndrome (ACS) and underwent primary percutaneous coronary intervention. MGP and BMP-4 levels were significantly elevated when compared to subjects with normal coronary arteries. PMID: 28605143 genetic association studies in population in Greece: Data suggest that an SNP in promoter region of matrix Gla protein (rs1,800,802; T-138C) is associated with diabetic angiopathy (as indicated by carotid intima media thickness) in patients with type 2 diabetes and diabetic nephropathy. PMID: 28734846 This study concluded that diabetes coexisting with renal disease leads to extreme vascular calcification expressed by elevated MGP levels, resulting in higher frequency of cardiovascular disease in comparison to CKD patients without diabetes. PMID: 28654853 Increased desphospho-uncarboxylated matrix Gla protein, which is a circulating biomarker of vitamin K status and vascular calcification, is independently associated with aortic stiffness, but not with stiffness of distal muscular-type arteries. PMID: 26016598 Our results indicate that the association between the matrix Gla protein variant and increased risk for hand Osteoarthritis is caused by a lower expression of matrix Gla protein, which may increase the burden of hand Osteoarthritis by decreased inhibition of cartilage calcification. PMID: 28855172 Genetic variability in the MGP gene was associated with vascular recurrence in the Spanish population. PMID: 28411264 MGP is significantly repressed by miR-155 in breast cancer MCF-7 cells, and concomitantly there is a stimulation of cell proliferation and cell invasiveness. PMID: 27009385 ectopic expression of Mgp in murine and human osteosarcoma cells led to a marked increase in lung metastasis. Abrogation of Mgp prevented lung metastatic activity, an effect that was rescued by forced expression. Mgp levels dramatically altered endothelial adhesion, trans-endothelial migration in vitro and tumour cell extravasation ability in vivo PMID: 27172275 MGP rs4236 [A/G] gene polymorphism was not to be associated with subgingival dental calculus. Also, that GCF MGP levels were detected higher in patients with subgingival dental calculus than those without subgingival dental calculus independently of polymorphism, may be the effect of adaptive mechanism to inhibit calculus formation. PMID: 27348051 The substitution of threonine by alanine due to MGP exon 4 Thr83Ala polymorphism is related to a decrease in the likelihood of arterial calcification in female persons in the Ukrainian population PMID: 27119839 Correlations of plasma desphosphorylated uncarboxylated matrix Gla protein (dp-ucMGP) with vascular calcification and vascular stiffness in chronic kidney disease. Plasma dp-ucMGP was positively associated with vascular calcification and might be utilized as an early marker for vascular calcification in CKD patients. PMID: 27951533 circulating dp-ucMGP and dp-cMGP may have a role in increasing risk of all-cause and cardiovascular mortality PMID: 24835435 It is assumed that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself. PMID: 25458708 Data shoed increased GAS6 and decreased MGP levels in hemodialysis patients, as mediators of induction or prevention of vascular calcification. PMID: 25957430 Altering NOTCH1 levels affected MGP mRNA and protein. PMID: 25871831 Uncarboxylated MGP in synovial fluid might serve as a novel biomarker for assessing knee osteoarthritis progression. PMID: 26771974 MGP expression is significantly lower in diseased relative to normal aortic valve interstitial cells. Lack of this important "anti-calcification" protein may contribute to calcification of the aortic valve. PMID: 25990696 Higher plasma dephosphorylated uncarboxylated MGP (reflective of lower vitamin K status) was associated with higher odds of meniscus damage, osteophytes, bone marrow lesions, and subarticular cysts. PMID: 25528106 High levels of desphospho-uncarboxylated MGP are independently and positively associated with arterial stiffness after adjustment for common cardiovascular risk factors, renal function, and age. PMID: 25987667 The association has been found between the ischemic atherothrombotic stroke and polymorphic variants of genes MGP and VKORC1. PMID: 26040031 MGP expression is impaired in patients with ankylosing spondylitis PMID: 25974989 The concentration of dephosphorylated-uncarboxylated Matrix Gla protein was higher in hemodialysis patients treated with vitamin K. PMID: 25190488 the findings of this prospective study among type 2 diabetic patients shows that high circulating dpucMGP levels are associated with increased cardiovascular diseases risk, especially with peripheral arterial disease and heart failure. PMID: 23877986 Matrix Gla protein gene functional polymorphisms is associated with loss of bone mineral density and progression of aortic calcification. PMID: 24281054 Inactive nonphosphorylated and uncarboxylated matrix Gla protein levels were followed in a Flemish population. They correlated causally with non-cancer mortality and coronary events but not total cardiovascular mortality. PMID: 25421980 Both mutations predict complete loss of MGP function. PMID: 24458983 High matrix Gla protein levels are associated with below-knee arterial calcification score in type 2 diabetes mellitus patients. PMID: 24762216 Vitamin K insufficiency, as assessed by high plasma matrix Gla protein concentrations, is associated with increased risk for cardiovascular disease independent of classical risk factors and vitamin D status. PMID: 24210635 Based on the study results, the MGP protein did not play an important role in the development of stenosis of coronary arteries. PMID: 24445527 The MGP-138CC genotype may be associated with slower progression of vascular calcification in maintenance hemodialysis patients PMID: 23504408 High MGP concentrations may be associated with more vascular calcification. PMID: 24029658 Higher circulating MGP levels could help identify minor carotid stenosis with calcification in a relatively homogenous risk population (i.e., postmenopausal women), regardless of underlying cardiovascular risk factors PMID: 22992285 The A/A-variant of MGP gene is associated with an increased risk of ischemic atherothrombotic stroke in the Ukrainian women. PMID: 24228496 rs1800802 (T > C) polymorphism within the MGP promoter is not related to stenosis of the coronary artery. PMID: 23563003 Genetic variants of MGP are associated with calcification on the arterial wall. PMID: 23677904 Circulating dp-ucMGP and t-ucMGP may serve as markers for the extent of coronary artery calcification, but these findings need to be confirmed PMID: 22819559 MGP is a multi-functional inhibitor of normal and abnormal angiogenesis that may function by coordinating with both Notch and BMP signaling pathways PMID: 23110920 MGP carboxylation remained much less in pseudoxanthoma elasticum fibroblasts. PMID: 23223140 Menaquinone supplementation dose-dependently decreases dephospho-uncarboxylated MGP concentrations, but does not affect other MGP species. PMID: 23062766 Increased risk of myocardial infarction associated with MGP ThrAla83 genotype observed elsewhere may be related to faster progression of subclinical coronary atherosclerosis. PMID: 23307874 findings showed that SNPrs4236 of the MGP gene is associated with kidney stones in the Chinese Han population, and influences the genetic susceptibility to kidney stones PMID: 23046575 the A/A-variant of MGP gene promotor is associated with an increased risk of ischemic atherothrombotic stroke in female persons in the Ukrainian population. PMID: 23233942 The change in serum fetuin-A, matrix Gla protein (MGP), and osteopontin (OPN) levels after intracerebral hemorrhage (ICH) indicates that these parameters play a role in the pathophysiological processes leading to an ICH. PMID: 22115341 Angiotensin II exacerbates vascular calcification through activation of transcription factors, and regulation of MGP and inflammatory cytokine expression in vascular smooth muscle cells. PMID: 22796540 There may be an association between hand osteoarthritis and genetic polymorphism at the matrix Gla protein (MGP) locus that is not reflected by total MGP serum concentrations. PMID: 21724703 MGP level correlated negatively with proinflammatory cytokines & acute phase proteins in acute pancreatitis, & positively with lipase, fetuin A, & albumin, indicating a possible role in calcium & phosphate metabolism disturbances in AP. PMID: 22239033 a dysregulated MGP system could be involved in left ventricular dysfunction in patients with chronic heart failure PMID: 21294711 Mgp gene deletion may have a role in arteriovenous malformations PMID: 21765215

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.